Neuropathic pain (NP) is a common form of human pain, often poorly responsive to analgesic medications. This chapter discusses the pathophysiology and conventional treatment of common categories of neuropathic pain and reviews the literature on botulinum neurotoxin (BoNT) efficacy in neuropathic pain. The level of efficacy for BoNT treatment in each category is defined according to the published guidelines of the American Academy of Neurology. The data on type A toxin (mostly onabotulinumtoxinA, onaA) indicates efficacy in postherpetic neuralgia and probable efficacy in post-traumatic neuralgia, and painful diabetic neuropathy. Retrospective studies and anecdotal observations suggest efficacy in residual limb pain of amputees, complex regional pain syndrome, and chemotherapy-induced allodynia. Controlled studies are necessary to assess the efficacy of BoNTs in these conditions. Much remains to be learned about the most effective dosage and technique of injection, optimum dilutions, and differences among BoNTs in the treatment of neuropathic pain.


Botulinum toxin Botulinum neurotoxin Neuropathic pain Pain Allodynia Postherpetic neuralgia Post-traumatic neuralgia Diabetic neuropathy Complex regional pain syndrome Phantom pain Residual pain 

Supplementary material

Video 3.1

Patient 3-1(postherpetic neuralgia). Grid-like injection of the right postauricular region (MOV 16826 kb)

Video 3.2

Patient 3-1. Interview with the patient with PHN, 2 years after treatment with onaA (MOV 130718 kb)

Video 3.3

Patient 3-2. Post-traumatic neuralgia: interview after two treatments (MOV 78315 kb)

Video 3.4

Patient 3-2. Post-traumatic neuralgia: subcutaneous injection of onaA into the pain area (third injection) (MOV 65903 kb)


  1. Alviar MJ, Hale T, Dungca M. Pharmacologic interventions for treating phantom limb pain. Cochrane Database Sys Rev. 2011;(12):CD006380. doi: 10.1002/14651858.CD006380.pub2. Review.
  2. Aoki RK, Francis J. Update on the nociceptive mechanism hypothesis and relate disorders. Park Relat Disord. 2011;17:S28–33.CrossRefGoogle Scholar
  3. Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain. 2013;29:857–64.CrossRefPubMedGoogle Scholar
  4. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain. 2002;18(6 Suppl):S177–81.CrossRefPubMedGoogle Scholar
  5. Baron R, Haendler G, Schulte H. Afferent large fiber polyneuropathy predicts the development of postherpetic neuralgia. Pain. 1997;73:231–8.CrossRefPubMedGoogle Scholar
  6. Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic neuropathic pain: a review. Pain Med. 2007;8 Suppl 2:S50–62. Review.CrossRefPubMedGoogle Scholar
  7. Boulton AJ. Diabetic neuropathy: classification, measurement and treatment. Curr Opin Endocrinol Diabetes Obes. 2007;14:141–5.CrossRefPubMedGoogle Scholar
  8. Carlen PL, Wall PD, Nadvorna H, Steinbach T. Phantom limbs and related phenomena in recent traumatic amputations. Neurology. 1978;28:211–7.CrossRefPubMedGoogle Scholar
  9. Chen WT, Yuan RY, Chiang SC, Sheu JJ, Yu JM, Tseng IJ, Yang SK, Chang HH, Hu CJ. OnabotulinumtoxinA improves tactile and mechanical pain perception in painful diabetic polyneuropathy. Clin J Pain. 2013;29:305–10.CrossRefPubMedGoogle Scholar
  10. Coderre TJ, Xanthos DN, Francis L, Bennett GJ. Chronic post-ischemia pain (CPIP): a novel animal model of complex regional pain syndrome-type I (CRPS-I; reflex sympathetic dystrophy) produced by prolonged hindpaw ischemia and reperfusion in the rat. Pain. 2004;112:94–105.CrossRefPubMedGoogle Scholar
  11. Cohen JI. Clinical practice: herpes zoster. N Engl J Med. 2013;369:255–63.CrossRefPubMedGoogle Scholar
  12. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin induced pain. Pain. 2004;107:125–33.CrossRefPubMedGoogle Scholar
  13. Del Valle L, Schwartzman RJ, Alexander G. Spinal cord histopathological alterations in a patient with longstanding complex regional pain syndrome. Brain Behav Immun. 2009;23:85–91.CrossRefPubMedGoogle Scholar
  14. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 1993;113:400–4.CrossRefPubMedGoogle Scholar
  15. French J, Gronseth G. Lost in a jungle of evidence: we need a compass. Neurology. 2008;71:1634–8.CrossRefPubMedGoogle Scholar
  16. Garrison CJ, Dougherty PM, Kajander KC, Carlton SM. Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res. 1991;565:1–7.CrossRefPubMedGoogle Scholar
  17. Goebel A, Baranowski A, Maurer K, Ghiai A, McCabe C, Ambler G. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial. Ann Intern Med. 2010;152:152–8.CrossRefPubMedGoogle Scholar
  18. Gronseth G, French J. Practice parameters and technology assessments: what they are, what they are not, and why you should care. Neurology. 2008;71:1639–43.CrossRefPubMedGoogle Scholar
  19. Haanpää M, Dastidar P, Weinberg A, Levin M, Miettinen A, Lapinlampi A, Laippala P, Nurmikko T. CSF and MRI findings in patients with acute herpes zoster. Neurology. 1998;51:1405–11.CrossRefPubMedGoogle Scholar
  20. Harden RN, Oaklander AL, Burton AW, Perez RS, Richardson K, Swan M, Barthel J, Costa B, Graciosa JR, Bruehl S, Reflex Sympathetic Dystrophy Syndrome Association. Complex regional pain syndrome: practical diagnostic and treatment guidelines. Pain Med. 2013;14:180–229.CrossRefPubMedGoogle Scholar
  21. Hsu E, Cohen SP. Postamputation pain: epidemiology, mechanisms, and treatment. J Pain Res. 2013;6:121–36.PubMedCentralPubMedGoogle Scholar
  22. Jensen TS, Krebs B, Nielsen J, Rasmussen P. Phantom limb, phantom pain and stump pain in amputees during the first 6 months following limb amputation. Pain. 1983;17:243–56.CrossRefPubMedGoogle Scholar
  23. Jin L, Kollewe K, Krampfl K, Dengler R, Mohammadi B. Treatment of phantom limb pain with botulinum toxin type A. Pain Med. 2009;10:300–3.CrossRefPubMedGoogle Scholar
  24. Katz J, Seltzer Z. Transition from acute to chronic postsurgical pain: risk factors and protective factors. Expert Rev Neurother. 2009;9:723–44.CrossRefPubMedGoogle Scholar
  25. Kern U, Martin C, Scheicher S, Müller H. Effects of botulinum toxin type B on stump pain and involuntary movements of the stump. J Phys Med Rehabil. 2004;83:396–9.CrossRefGoogle Scholar
  26. Kharkar S, Ambady P, Venkatesh Y, Schwartzman RJ. Complex regional pain syndrome: intramuscular botulinum toxin in case series and literature review. Pain Physician. 2011;14:419–24.PubMedGoogle Scholar
  27. Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101:366–70.CrossRefPubMedGoogle Scholar
  28. Magrinelli F, Zanette G, Tamburin S. Neuropathic pain: diagnosis and treatment. Pract Neurol. 2013;13:292–307.CrossRefPubMedGoogle Scholar
  29. McLachlan EM, Jänig W, Devor M, Michaelis M. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature. 1993;363:543–6.CrossRefPubMedGoogle Scholar
  30. Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007;120:2864–74.CrossRefPubMedGoogle Scholar
  31. Oaklander AL. The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. Pain. 2001;92:139–45.CrossRefPubMedGoogle Scholar
  32. Orestes P, Osuru HP, McIntire WE, Jacus MO, Salajegheh R, Jagodic MM, Choe W, Lee J, Lee SS, Rose KE, Poiro N, Digruccio MR, Krishnan K, Covey DF, Lee JH, Barrett PQ, Jevtovic-Todorovic V, Todorovic SM. Reversal of neuropathic pain in diabetes by targeting glycosylation of cav3.2 T-type calcium channels. Diabetes. 2013;62:3828–38.CrossRefPubMedCentralPubMedGoogle Scholar
  33. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6:356–63.CrossRefPubMedGoogle Scholar
  34. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann Jr JW, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL, Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84.CrossRefPubMedGoogle Scholar
  35. Rand MJ, Whaler BC. Impairment of sympathetic transmission by botulinum toxin. Nature. 1965;206:588–91.CrossRefPubMedGoogle Scholar
  36. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64:274–83.CrossRefPubMedGoogle Scholar
  37. Romanovsky D, Cruz NF, Dienel GA, Dobretsov M. Mechanical hyperalgesia correlates with insulin deficiency in normoglycemic streptozotocin-treated rats. Neurobiol Dis. 2006;24:384–94.CrossRefPubMedGoogle Scholar
  38. Safarpour D, Jabbari B. Botulinum toxin A (Botox) for treatment of proximal myofascial pain in complex regional pain syndrome: two cases. Pain Med. 2010;11:1415–8.CrossRefPubMedGoogle Scholar
  39. Safarpour D, Salardini A, Richardson D, Jabbari B. Botulinum toxin A for treatment of allodynia of complex regional pain syndrome: a pilot study. Pain Med. 2010;11:1411–4.CrossRefPubMedGoogle Scholar
  40. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain. 2009;147:107–15.CrossRefPubMedGoogle Scholar
  41. Sherman RA, Sherman CJ, Parker L. Chronic phantom and stump pain among American veterans. Pain. 1984;18:83–95.CrossRefPubMedGoogle Scholar
  42. Shin MC, Wakita M, Xie DJ, Yamaga T, Iwata S, Torii Y, Harakawa T, Ginnaga A. Inhibition of membrane Na+ channels by A type botulinum toxin at femtomolar concentrations in central and peripheral neurons. J Pharmacol Sci. 2012;118:33–42.CrossRefPubMedGoogle Scholar
  43. Thyregod HG, Rowbotham MC, Peters M, Possehn J, Berro M, Petersen KL. Natural history of pain following herpes zoster. Pain. 2007;128:148–56.CrossRefPubMedCentralPubMedGoogle Scholar
  44. Todd AJ, Sullivan AC. Light microscope study of the coexistence of GABA-like and glycine-like immunoreactivities in the spinal cord of the rat. J Comp Neurol. 1990;296:496–505.CrossRefPubMedGoogle Scholar
  45. Treede RD. Peripheral and central mechanisms of neuropathic pain. In: Simpson, Mc Arthur, Dworkin, editors. Neuropathic pain –mechanisms, diagnosis and treatment. New York: Oxford Publisher; 2012. p. 14–24. Chapter 2.CrossRefGoogle Scholar
  46. Weber M, Birklein F, Neundörfer B, Schmelz M. Facilitated neurogenic inflammation in complex regional pain syndrome. Pain. 2001;91:251–7.CrossRefPubMedGoogle Scholar
  47. Whitley RJ, Weiss H, Gnann Jr JW, Tyring S, Mertz GJ, Pappas PG, Schleupner CJ, Hayden F, Wolf J, Soong SJ. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996;125:376–83.CrossRefPubMedGoogle Scholar
  48. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis. 1996;22:341–7.CrossRefPubMedGoogle Scholar
  49. Wu H, Sultana R, Taylor KB, Szabo A. A prospective randomized double-blinded pilot study to examine the effect of botulinum toxin type A injection versus lidocaine/depomedrol injection on residual and phantom limb pain: initial report. Clin J Pain. 2012;28:108–12.CrossRefPubMedGoogle Scholar
  50. Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med. 2010;11:1827–33.CrossRefPubMedGoogle Scholar
  51. Yaksh TL, Caplan SR. Physiology and pharmacology of neuropathic pain. Anesth Clin N Am. 1997;15:335–52.CrossRefGoogle Scholar
  52. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341–9.CrossRefPubMedGoogle Scholar
  53. Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, Hu CJ. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72:1473–8.CrossRefPubMedGoogle Scholar
  54. Ziegler-Graham K, MacKenzie EJ, Ephraim PL, Travison TG, Brookmeyer R. Estimating the prevalence of limb loss in the United States: 2005 to 2050. Arch Phys Med Rehabil. 2008;89:422–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Bahman Jabbari
    • 1
  1. 1.Botulinum Toxin Treatment ProgramYale School of MedicineNew HavenUSA

Personalised recommendations